Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 15/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600738 | 0.80 | RIPK2 (0.38) | RIPK2KCNH2LRRK2 | |
| SCHEMBL600481 | 0.78 | RIPK2 (0.63) | RIPK2KCNH2ROCK1GAKLCK | |
| SCHEMBL18841397 | 0.77 | RIPK2 (0.44) | RIPK2KCNH2ROCK1LRRK2 | |
| SCHEMBL12496294 | 0.77 | RIPK2 (0.56) | RIPK2KCNH2ROCK1LRRK2GAK | |
| SCHEMBL10106406 | 0.76 | RIPK2 (0.52) | RIPK2KCNH2ROCK1LRRK2GAK | |
| SCHEMBL10106405 | 0.76 | RIPK2 (0.52) | RIPK2KCNH2ROCK1LRRK2GAK | |
| SCHEMBL600928 | 0.76 | RIPK2 (0.65) | RIPK2KCNH2ROCK1LRRK2GAK | |
| SCHEMBL18670879 | 0.74 | RIPK2 (0.53) | RIPK2KCNH2ROCK1LRRK2GAK | |
| SCHEMBL14717887 | 0.73 | RIPK2 (0.52) | RIPK2TGFBR1RIPK3 | |
| SCHEMBL599871 | 0.73 | RIPK2 (0.64) | RIPK2KCNH2ROCK1GAKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| EP-2603218-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RIPK2 480/4885KCNH2 824/4885ROCK1 339/4885 |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RIPK2 480/4885KCNH2 824/4885ROCK1 339/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | RIPK2 480/4885KCNH2 824/4885ROCK1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.